Trevi Therapeutics (TRVI)
(Delayed Data from NSDQ)
$7.42 USD
+0.12 (1.64%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $7.42 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Trevi Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
TRVI 7.42 +0.12(1.64%)
Will TRVI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRVI
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
TRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
Other News for TRVI
Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
TRVI Receives Updated Analyst Rating from Raymond James | TRVI Stock News
Trevi Therapeutics price target lowered by $2 at Raymond James, here's why
Needham Lowers Price Target for Trevi Therapeutics (TRVI) While Maintaining Buy Rating | TRVI ...